CR20190274A - Formulaciones liposomales para interacciones farmacológicas contra carcinoma del tracto superior - Google Patents

Formulaciones liposomales para interacciones farmacológicas contra carcinoma del tracto superior

Info

Publication number
CR20190274A
CR20190274A CR20190274A CR20190274A CR20190274A CR 20190274 A CR20190274 A CR 20190274A CR 20190274 A CR20190274 A CR 20190274A CR 20190274 A CR20190274 A CR 20190274A CR 20190274 A CR20190274 A CR 20190274A
Authority
CR
Costa Rica
Prior art keywords
methods
ureter
renal pelvis
balloon
catheter
Prior art date
Application number
CR20190274A
Other languages
English (en)
Inventor
Michael G Oefelein
Guru V Betageri
Natarajan Venkatesan
Original Assignee
Univ Western Health Sciences
Tesorx Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Health Sciences, Tesorx Pharma Llc filed Critical Univ Western Health Sciences
Publication of CR20190274A publication Critical patent/CR20190274A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1089—Urethra

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a métodos para administrar de manera local un agente quimioterapéutico a un carcinoma urotelial del tracto superior (UTUC). Los métodos implican colocar un catéter con balón que tiene un canal de trabajo y un balón dentro del uréter/pelvis renal a través de acceso 5 retrógrado o anterógrado; inflar el balón del catéter para obstruir temporalmente el uréter; infusionar (instilar) una formulación liposomal que incluye un agente quimioterapéutico dentro del canal de trabajo del catéter; y permitir que la formulación liposomal infusionada permanezca en el uréter y/o pelvis renal durante un tiempo suficiente para permitir que al menos una parte de la formulación liposomal se adhiera a la pared urotelial. En los métodos de la invención, al menos 10 una parte de la formulación con agente quimioterapéutico infusionado se adhiere a la pared urotelial mientras es instilada y permanece en el uréter y/o pelvis renal. Los métodos descritos se pueden realizar como una terapia adyuvante con respecto a otros métodos para tratar UTUC, tales como extirpación o ablación ureteroscópica del tumor.The invention relates to methods for locally delivering a chemotherapeutic agent to an upper tract urothelial carcinoma (UTUC). The methods involve placing a balloon catheter that has a working channel and a balloon into the ureter/renal pelvis via retrograde or antegrade ureteral access; inflating the catheter balloon to temporarily obstruct the ureter; infusing (instilling) a liposomal formulation that includes a chemotherapeutic agent into the working channel of the catheter; and allowing the infused liposomal formulation to dwell in the ureter and/or renal pelvis for a time sufficient to allow at least a portion of the liposomal formulation to adhere to the urothelial wall. In the methods of the invention, at least a portion of the infused chemotherapeutic-agent formulation adheres to the urothelial wall while it is instilled and dwells in the ureter and/or renal pelvis. The disclosed methods can be performed as an adjuvant therapy to other methods of treating UTUC, such as ureteroscopic ablation or resection of the tumor.
CR20190274A 2016-11-11 2017-11-10 Formulaciones liposomales para interacciones farmacológicas contra carcinoma del tracto superior CR20190274A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421055P 2016-11-11 2016-11-11
PCT/US2017/061047 WO2018089759A1 (en) 2016-11-11 2017-11-10 Methods of treating upper tract urothelial carcinomas

Publications (1)

Publication Number Publication Date
CR20190274A true CR20190274A (es) 2019-07-29

Family

ID=62109985

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190274A CR20190274A (es) 2016-11-11 2017-11-10 Formulaciones liposomales para interacciones farmacológicas contra carcinoma del tracto superior

Country Status (16)

Country Link
US (1) US20190343763A1 (es)
EP (1) EP3538074B1 (es)
JP (1) JP7096553B2 (es)
KR (1) KR20190084284A (es)
CN (1) CN110167533A (es)
AU (1) AU2017358049B2 (es)
BR (1) BR112019009616A2 (es)
CA (1) CA3043620A1 (es)
CL (1) CL2019001262A1 (es)
CO (1) CO2019005881A2 (es)
CR (1) CR20190274A (es)
EA (1) EA201991143A1 (es)
MX (1) MX2019005185A (es)
NZ (1) NZ753214A (es)
PE (1) PE20191653A1 (es)
WO (1) WO2018089759A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017205337B2 (en) * 2016-01-07 2022-09-08 Tesorx Pharma, Llc Formulations for treating bladder cancer
GB201900389D0 (en) 2019-01-11 2019-02-27 Queens Univ Of Belfast Solvent and water-free lipid-based nanoparticles and their methods of manufacture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759058B1 (en) 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
PL370867A1 (en) 2001-09-24 2005-05-30 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
JP5645340B2 (ja) 2003-10-15 2014-12-24 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ 活性成分を含有するカチオンリポソームの投与方法
US20090171241A1 (en) * 2006-03-03 2009-07-02 Garcia Maurice M System and method for urinary tract cell collection, diagnosis, and chemotherapy
US20100034874A1 (en) 2006-12-08 2010-02-11 Katayama Chemical Industries Co., Ltd. Liposome encapsulating ammine-platinum complex at high concentration, and method for production of the liposome
CA2681302C (en) 2007-03-19 2013-07-23 Dhiraj Khattar Proliposomal and liposomal compositions of poorly water-soluble compounds
CN101322689B (zh) * 2007-06-11 2012-10-24 江苏先声药物研究有限公司 一种多西他赛长循环脂质体及其冻干粉针的制备方法
NZ721900A (en) 2012-05-09 2018-01-26 Univ Western Health Sciences Proliposomal testosterone formulations
US20140172118A1 (en) 2012-12-19 2014-06-19 Cook Medical Technologies Llc Bioactive Compositions, Bioactive Eluting Devices and Methods of Use Thereof
US20160175559A1 (en) * 2014-12-23 2016-06-23 Cook Medical Technologies Llc Medical Devices for Delivery and Retention of Bioactive Agents
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
EP4193939A1 (en) * 2015-03-26 2023-06-14 Vensica Medical Ltd. Ultrasonic urinary bladder drug delivery
JP2018517454A (ja) 2015-04-24 2018-07-05 ウロトロニック・インコーポレイテッドＵｒｏｔｒｏｎｉｃ， Ｉｎｃ． 非血管狭窄のための薬物コーティングされたバルーンカテーテル
JP6249987B2 (ja) * 2015-05-13 2017-12-20 ルトニックス，インコーポレーテッド 医療用具のための薬物放出コーティング
AU2017205337B2 (en) 2016-01-07 2022-09-08 Tesorx Pharma, Llc Formulations for treating bladder cancer

Also Published As

Publication number Publication date
WO2018089759A1 (en) 2018-05-17
NZ753214A (en) 2022-02-25
CL2019001262A1 (es) 2019-07-26
EP3538074A4 (en) 2020-06-24
JP7096553B2 (ja) 2022-07-06
KR20190084284A (ko) 2019-07-16
EP3538074B1 (en) 2023-07-26
JP2019534305A (ja) 2019-11-28
CN110167533A (zh) 2019-08-23
CA3043620A1 (en) 2018-05-17
PE20191653A1 (es) 2019-11-07
US20190343763A1 (en) 2019-11-14
BR112019009616A2 (pt) 2019-08-13
CO2019005881A2 (es) 2019-08-30
AU2017358049A1 (en) 2019-05-30
EA201991143A1 (ru) 2019-10-31
AU2017358049B2 (en) 2023-11-09
MX2019005185A (es) 2019-07-01
EP3538074A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
WO2015186003A3 (en) Methods and devices for treating pulmonary edema
CL2020000106A1 (es) Sondas ureterales y vesicales y métodos para inducir presión negativa para aumentar la perfusión renal. (divisional solicitud 201800153)
BR112016028550A2 (pt) guia e introdutor do cateter com agulha sub-retinal tangencial
MX2020011581A (es) Catéter de globo.
CR20190274A (es) Formulaciones liposomales para interacciones farmacológicas contra carcinoma del tracto superior
SG10201807070YA (en) Respiratory mask with nasogastric tube path
WO2016015001A3 (en) Combination fluid instillation and negative pressure dressing
DK1558324T3 (da) Vakuumindretning til behandling af væv nær et kropshulrum
BR112018003616A2 (pt) método de entrega de líquidos para sistema de rf resfriado
BR112016028641A2 (pt) ?método para tratar câncer?
EA201990976A1 (ru) Новый способ профилактического лечения непроизвольной потери массы
EA202091143A1 (ru) Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина
MX2019007729A (es) Reducción del daño de la quimioterapia y aumento de las tasas de destrucción de cáncer usando radiación entremezclada de baja dosis.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
Rana et al. Infected pancreatic pseudocyst of spleen successfully treated by combined endoscopic transpapillary stent placement and transmural aspiration
JP2014008241A (ja) バルーンカテーテルおよびバルーンカテーテルの製造方法
MX2020004518A (es) Suministro asistido de manera magnética al interior y a través de la piel.
CN203763241U (zh) 激光吸引器水脉冲一体的皮下介入腋臭治疗装置
MY197942A (en) Adjuvant therapy for use in prostate cancer treatment
Maheshwari et al. Randomized and prospective trial comparing tract creation using plasma vaporization with balloon dilatation in percutaneous nephrolithotomy
Ohlmann et al. Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. Lancet Oncol 2015; 16: 76-86
Kim et al. Analysis of Postoperative Complications of Superficial Liposuction
Da-Costa Chelation and Ozone Combination–the knock-out blow in treating ischemic heart disease
CN105663242A (zh) 一种针对慢性单纯性鼻炎的食疗配方
Björk The use of the Seldinger technic for percutaneous introduction of drainage tubes into thoracic cavities